167 related articles for article (PubMed ID: 17868016)
21. The genetics of clinical outcome in multiple sclerosis.
Ramagopalan SV; Deluca GC; Degenhardt A; Ebers GC
J Neuroimmunol; 2008 Sep; 201-202():183-99. PubMed ID: 18632165
[TBL] [Abstract][Full Text] [Related]
22. Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility.
Fernandez-Morera JL; Rodriguez-Rodero S; Tunon A; Martinez-Borra J; Vidal-Castineira JR; Lopez-Vazquez A; Rodrigo L; Rodrigo P; González S; Lahoz CH; Lopez-Larrea C
Tissue Antigens; 2008 Jul; 72(1):54-9. PubMed ID: 18588574
[TBL] [Abstract][Full Text] [Related]
23. The genetics of multiple sclerosis.
Hillert J
Results Probl Cell Differ; 2010; 51():1-19. PubMed ID: 19582414
[TBL] [Abstract][Full Text] [Related]
24. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.
Sarial S; Shokrgozar MA; Amirzargar A; Shokri F; Radfar J; Zohrevand P; Arjang Z; Sahraian MA; Lotfi J
Iran J Allergy Asthma Immunol; 2008 Mar; 7(1):37-40. PubMed ID: 18322311
[TBL] [Abstract][Full Text] [Related]
25. New insights into the genetics of multiple sclerosis.
Baranzini SE; Oksenberg JR; Hauser SL
J Rehabil Res Dev; 2002; 39(2):201-9. PubMed ID: 12051464
[TBL] [Abstract][Full Text] [Related]
26. Translation towards personalized medicine in Multiple Sclerosis.
Miller A; Avidan N; Tzunz-Henig N; Glass-Marmor L; Lejbkowicz I; Pinter RY; Paperna T
J Neurol Sci; 2008 Nov; 274(1-2):68-75. PubMed ID: 18789804
[TBL] [Abstract][Full Text] [Related]
27. KIR2DL4 (CD158d) polymorphisms and susceptibility to multiple sclerosis.
Goris A; Dobosi R; Boonen S; Nagels G; Dubois B
J Neuroimmunol; 2009 May; 210(1-2):113-5. PubMed ID: 19304328
[TBL] [Abstract][Full Text] [Related]
28. Genes, environment, and susceptibility to multiple sclerosis.
Sotgiu S; Pugliatti M; Fois ML; Arru G; Sanna A; Sotgiu MA; Rosati G
Neurobiol Dis; 2004 Nov; 17(2):131-43. PubMed ID: 15474351
[TBL] [Abstract][Full Text] [Related]
29. Genomics and new targets for multiple sclerosis.
Baranzini SE; Oksenberg JR
Pharmacogenomics; 2005 Mar; 6(2):151-61. PubMed ID: 15882133
[TBL] [Abstract][Full Text] [Related]
30. BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences.
Mirowska-Guzel D; Mach A; Gromadzka G; Czlonkowski A; Czlonkowska A
J Neuroimmunol; 2008 Jan; 193(1-2):170-2. PubMed ID: 18061279
[TBL] [Abstract][Full Text] [Related]
31. Role of genetics in the diagnosis and treatment of epilepsy.
Ferraro TN; Dlugos DJ; Buono RJ
Expert Rev Neurother; 2006 Dec; 6(12):1789-800. PubMed ID: 17181426
[TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.
Wingerchuk DM; Weinshenker BG
Neuroimaging Clin N Am; 2000 Nov; 10(4):611-24 ,vii. PubMed ID: 11359715
[TBL] [Abstract][Full Text] [Related]
33. Epidemiologic studies of multiple sclerosis: a review.
Kahana E
Biomed Pharmacother; 2000 Mar; 54(2):100-2. PubMed ID: 10759294
[TBL] [Abstract][Full Text] [Related]
34. The interleukin 23 receptor gene in multiple sclerosis: a case-control study.
Roos IM; Kockum I; Hillert J
J Neuroimmunol; 2008 Feb; 194(1-2):173-80. PubMed ID: 18164077
[TBL] [Abstract][Full Text] [Related]
35. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis.
Galimberti D; Scalabrini D; Fenoglio C; De Riz M; Comi C; Venturelli E; Cortini F; Piola M; Leone M; Dianzani U; D'Alfonso S; Monaco F; Bresolin N; Scarpini E
J Neurol Sci; 2008 Apr; 267(1-2):86-90. PubMed ID: 17967467
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
37. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.
Papadopoulos N; Kinzler KW; Vogelstein B
Nat Biotechnol; 2006 Aug; 24(8):985-95. PubMed ID: 16900147
[TBL] [Abstract][Full Text] [Related]
38. CTLA-4 and multiple sclerosis: the A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population.
Wray BN; Stankovich J; Whittock L; Dwyer T; Ponsonby AL; van der Mei IA; Taylor B; Dickinson J; Foote S; McMorran BJ
J Neuroimmunol; 2008 May; 196(1-2):139-42. PubMed ID: 18378005
[TBL] [Abstract][Full Text] [Related]
39. Genetics and natural history of multiple sclerosis.
Kantarci OH
Semin Neurol; 2008 Feb; 28(1):7-16. PubMed ID: 18256983
[TBL] [Abstract][Full Text] [Related]
40. Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis.
Ramagopalan SV; Byrnes JK; Dyment DA; Guimond C; Handunnetthi L; Disanto G; Yee IM; Ebers GC; Sadovnick AD
J Hum Genet; 2009 Sep; 54(9):547-9. PubMed ID: 19629136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
